SAB Biotherapeutics has developed a first-of-its-kind therapeutic engine—unleashing the power of the body’s native biological defense system to produce immunotherapies that truly match and overpower the complexity, diversity, and evolution of human disease.

This new class of immunotherapies opens the door to new medicines that are safer, more effective, and longer lasting than current antibody therapies.

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.

More here

Source: SAB Biotherapeutics